Clinical Trials Logo

Clinical Trial Summary

MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders. The development program is based on nonclinical evidence that MW151 improves neurocognitive outcomes in animal models of radiation-induced cognitive impairment, Alzheimer's disease, and other central nervous system (CNS) disorders. The present study will provide safety and pharmacokinetic (PK) information on single ascending doses to support decisions for continued clinical development.


Clinical Trial Description

The primary objective of this trial is to assess the safety and tolerability of single ascending doses of MW151 when administered orally to healthy adults. Subjects will be screened prior to inpatient admission. Subjects will be admitted to the inpatient clinic on the day prior to dosing (Day -1) and will remain in the unit until discharge on Day 3. A follow-up visit will be done on Day 7. A single dose of study drug or placebo will be administered on Day 1. Healthy adult female subjects will be randomly assigned to one of 5 dose cohorts (8 subjects each). Each subject will receive a single dose of MW151 (10-160mg) or placebo under fasted conditions. Following a review of safety and tolerability data for the first 24 hours of dosing in each cohort (including reported adverse events (AEs), physical examination findings, clinical laboratory results, vital signs, and electrocardiograms (ECGs), the remaining 6 subjects will be randomized in a 5:1 ratio. Dosing of the remaining subjects in a cohort may proceed after review of sentinel subject safety data collected during the first 24 hours of dosing and determination that no stopping rules are met. The remaining subjects in each cohort will be dosed sequentially, not simultaneously. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04120233
Study type Interventional
Source University of Kentucky
Contact
Status Completed
Phase Phase 1
Start date October 22, 2019
Completion date September 16, 2021

See also
  Status Clinical Trial Phase
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04696081 - Atrial Fibrillation in Active Cancer Patients
Active, not recruiting NCT03651778 - GHB Poisoning and Poisoning Induced by Others
Recruiting NCT01965275 - High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs Phase 2
Completed NCT01614080 - Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA N/A
Recruiting NCT04659343 - TDM for Optimized Outcome in Patients With mRCC.
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT01135680 - Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100 Phase 1
Completed NCT03947034 - Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
Recruiting NCT03885388 - Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6 Phase 2/Phase 3
Completed NCT00491595 - Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women Phase 1
Recruiting NCT03469063 - Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients N/A
Not yet recruiting NCT04671589 - Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. Phase 4
Completed NCT03280368 - Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
Withdrawn NCT01374061 - Pre Hospital Evaluation of Video Laryngoscopy Phase 4
Completed NCT03994302 - Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
Completed NCT03392311 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Terminated NCT00090844 - Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer Phase 2
Terminated NCT00213642 - Tc-99m Renography and Cisplatin-induced Nephrotoxicity N/A
Terminated NCT05022797 - Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS Phase 2